{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:19Z","timestamp":1793686339346,"version":"4.5.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antiphospholipid syndrome (APS) is an autoimmune response characterized clinically by arterial or venous thrombosis. One of the rare and series forms of APS is the catastrophic APS (CAPS). The incidence of CAPS has been reported in 0.8% of patients with APS. There have been very few case reports with cardiac involvement in CAPS. Common cardiac manifestations include valvular thickening and lesions, coronary artery disease, and myocardial infarction due to microvascular thrombosis. Here, we are reporting a case of CAPS associated with heart failure and a literature review of similar cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 24-year-old woman with a history of APS presented with shortness of breath and right-sided pleuritic chest pain. Computed tomography pulmonary angiogram revealed new pulmonary emboli in the right lung. After 5 days, she developed high-grade fever with negative infectious workup, acute hypoxic respiratory failure with pulmonary oedema, shock, acute kidney injury, and transthoracic echocardiography showed reduced ejection fraction and global hypokinesia. The constellation of multi-organ failure, symptoms within a week, the presence of antiphospholipid antibodies, and exclusion of other causes, CAPS was diagnosed. The patient showed significant improvement with pulse steroids, IV plasmapheresis and got discharged on oral prednisone taper and anticoagulation with home health.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There are different cardiac complications associated with CAPS, including congestive heart failure, acute coronary syndrome, valvular lesions, and thrombus. Heart failure management in CAPS includes triple therapy of intravenous immune globulin, IV plasmapheresis, and corticosteroids rather than conventional treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytac199","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T08:07:56Z","timestamp":1652256476000},"source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular complications of catastrophic antiphospholipid syndrome: a case report and review of literature"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7168-2550","authenticated-orcid":false,"given":"Nitish","family":"Mittal","sequence":"first","affiliation":[{"name":"Texas Tech University Health Science Center, School of Medicine, Class 2022 , Lubbock, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-7072","authenticated-orcid":false,"given":"Mostafa","family":"Abohelwa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center , Lubbock, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Rubayat","family":"Rahman","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Cardiology Division, Texas Tech University Health Sciences Center , Lubbock, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Shurmur","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Cardiology Division, Texas Tech University Health Sciences Center , Lubbock, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"2022053116394644100_ytac199-B1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"2013","author":"Lim","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2022053116394644100_ytac199-B2","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/art.41401","article-title":"Antiphospholipid syndrome is still a rare disease-estimated prevalence in the piedmont and Aosta Valley regions of Northwest Italy: comment on the article by Duarte-Garc\u00eda et al.","volume":"72","author":"Radin","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022053116394644100_ytac199-B3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022053116394644100_ytac199-B4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.autrev.2014.11.003","article-title":"Antiphospholipid syndrome and the heart: a case series and literature review","volume":"14","author":"Denas","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2022053116394644100_ytac199-B5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"2022053116394644100_ytac199-B6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Eng J Med"},{"key":"2022053116394644100_ytac199-B7","first-page":"162","article-title":"Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome","volume":"16","author":"Djokovic","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"2022053116394644100_ytac199-B8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"2022053116394644100_ytac199-B9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/jth.13947","article-title":"Thrombocytopenia in high-risk patients with antiphospholipid syndrome","volume":"16","author":"Pontara","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2022053116394644100_ytac199-B10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/01.CIR.93.8.1579","article-title":"Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome","volume":"93","author":"Hojnik","year":"1996","journal-title":"Circulation"},{"key":"2022053116394644100_ytac199-B11","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022053116394644100_ytac199-B12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0961203314540764","article-title":"Catastrophic antiphospholipid syndrome: task force report summary","volume":"23","author":"Cervera","year":"2014","journal-title":"Lupus"},{"key":"2022053116394644100_ytac199-B13","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022053116394644100_ytac199-B14","first-page":"355","article-title":"Rituximab treatment for resistant antiphospholipid syndrome","volume":"33","author":"Rubenstein","year":"2006","journal-title":"J Rheumatol"},{"key":"2022053116394644100_ytac199-B15","article-title":"Catastrophic antiphospholipid syndrome associated with mitral valve thrombosis","author":"Hassan","year":"2021","journal-title":"J Investig Med"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytac199\/43668512\/ytac199.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytac199\/43846053\/ytac199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytac199\/43846053\/ytac199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T18:33:09Z","timestamp":1654021989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytac199\/6583508"}},"subtitle":[],"editor":[{"given":"Sameh","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Edin","family":"Begic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Kyriakos","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deborah","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Daniel","family":"Tardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Jonathan","family":"Senior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytac199","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,5,1]]},"article-number":"ytac199"}}